News

UBS Reaffirms Neutral Rating on Harley-Davidson with Price Target

UBS Reaffirms Neutral Rating on Harley-Davidson with Price Target

UBS Maintains Neutral Rating on Harley-Davidson Shares

UBS has reiterated its Neutral stance on Harley-Davidson (NYSE: HOG) shares, reaffirming a price target of $40.00. The firm’s recent insights suggest that the iconic motorcycle manufacturer may have to lower its shipment guidance in the near term due to various market challenges.

Challenges in Shipment and Performance

According to UBS's analysis, Harley-Davidson's performance has shown signs of decline through the third quarter. The strong year-over-year results reported in July were partly due to favorable comparisons stemming from previous production disruptions in the prior two Junes. Despite a slight revision in shipment guidance earlier, UBS indicates that a further adjustment may soon be necessary.

Dealers have reported a concerning trend of not receiving new motorcycle deliveries for several weeks, raising implications of an unusually early halt in shipments for the year. This situation suggests that there may be more significant operational issues than previously anticipated.

Financial Outlook and Recent Developments

In other relevant financial news, Harley-Davidson has recently seen mixed results. While DA Davidson has projected that the company will report third-quarter earnings below consensus expectations, they continue to hold a Buy rating. They anticipate adjustments in Harley-Davidson's full-year 2024 guidance as dealer inventories undergo destocking.

On a more positive note, Harley-Davidson's Q2 profit managed to surpass market expectations, heavily influenced by strong sales in their high-end Touring motorcycle segment, resulting in a declared Q3 dividend of $0.1725 per share. Furthermore, the company is shifting production to Thailand and initiating a $1 billion share repurchase plan, signaling a proactive approach to managing their operations and financial health.

Government Support and Analyst Activity

A notable part of Harley-Davidson's strategic shift includes receiving an $89 million grant from the government for expanding their Pennsylvania plant dedicated to electric motorcycle manufacturing. This move reflects the broader industry trend toward electrification, positioning the company for future growth.

Analysts have been actively reassessing the stock, with Baird recently downgrading its rating on Harley-Davidson from Outperform to Neutral due to concerns regarding retail performance and inventory levels. Conversely, Citi and UBS have raised their target prices, reflecting a more optimistic outlook based on the company's recent strategic initiatives.

Market Performance Insights

Recent InvestingPro data highlights the current volatility surrounding Harley-Davidson's stock. The company's P/E ratio stands at 6.86, indicating it is trading at a relatively low earnings multiple, which corresponds with concerns voiced by UBS regarding potential reductions in shipment guidance.

In terms of market performance, Harley-Davidson's stock experienced a significant drop of 11.07% in total return over the past week. This decline likely reflects investor apprehension concerning the communication from UBS about shipment and inventory statuses.

Despite facing these headwinds, it is important to note that Harley-Davidson has a strong track record of maintaining dividend payments for 32 consecutive years, offering an appealing dividend yield of 2.04%. This factor remains attractive for income-focused investors, underscoring resilience even amid operational challenges.

Frequently Asked Questions

What is UBS's current rating on Harley-Davidson?

UBS has maintained a Neutral rating on Harley-Davidson (NYSE: HOG) shares with a price target of $40.00.

What challenges is Harley-Davidson facing recently?

Harley-Davidson is experiencing a potential decline in performance, a halt in new deliveries, and may need to reduce shipment guidance.

How has Harley-Davidson's stock performed lately?

The stock has seen some volatility, with a total return of -11.07% reported over the past week.

What initiatives is Harley-Davidson pursuing?

Harley-Davidson is shifting production to Thailand, launching a $1 billion share repurchase plan, and expanding its electric motorcycle manufacturing operations.

What is Harley-Davidson's dividend yield?

The company currently offers a dividend yield of 2.04%, which demonstrates its commitment to returning value to shareholders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading